This program is studying ANG003 (formerly SNSP003), a non-porcine (not pig-derived) enzyme replacement therapy for individuals with CF who have exocrine pancreatic insufficiency. It is a man-made version of a lipase enzyme taken from bacteria, and it does not contain any animal products.

ANG003 may improve dosing convenience by reducing pill burden compared to current porcine-based pancreatic enzyme replacement therapies (PERT). ANG003 is also being developed in a formulation for pediatric and adult patients who are unable to swallow capsules.

Status

A Phase 1 study to evaluate the safety, tolerability, and effectiveness of a single dose of ANG003 was completed.

Sponsor

This program is sponsored by Anagram Therapeutics (formerly known as Synspira Therapeutics) and partially funded by the Cystic Fibrosis Foundation. It is being conducted through the Therapeutics Development Network.